CH684630A5 - Pharmaceutical composition based on trace elements - Google Patents
Pharmaceutical composition based on trace elements Download PDFInfo
- Publication number
- CH684630A5 CH684630A5 CH2606/92A CH260692A CH684630A5 CH 684630 A5 CH684630 A5 CH 684630A5 CH 2606/92 A CH2606/92 A CH 2606/92A CH 260692 A CH260692 A CH 260692A CH 684630 A5 CH684630 A5 CH 684630A5
- Authority
- CH
- Switzerland
- Prior art keywords
- magnesium
- silver
- gold
- pharmaceutical composition
- parts
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 12
- 235000013619 trace mineral Nutrition 0.000 title description 8
- 239000011573 trace mineral Substances 0.000 title description 8
- 239000011777 magnesium Chemical class 0.000 claims abstract description 21
- 229910052709 silver Chemical class 0.000 claims abstract description 21
- 239000004332 silver Chemical class 0.000 claims abstract description 21
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 20
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical class [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229910052737 gold Inorganic materials 0.000 claims abstract description 19
- 239000010931 gold Substances 0.000 claims abstract description 19
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims abstract description 8
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical class [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims abstract description 5
- 239000001755 magnesium gluconate Substances 0.000 claims abstract description 4
- 235000015778 magnesium gluconate Nutrition 0.000 claims abstract description 4
- 235000019341 magnesium sulphate Nutrition 0.000 claims abstract description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims abstract description 3
- 159000000003 magnesium salts Chemical class 0.000 claims abstract description 3
- CQLFBEKRDQMJLZ-UHFFFAOYSA-M silver acetate Chemical compound [Ag+].CC([O-])=O CQLFBEKRDQMJLZ-UHFFFAOYSA-M 0.000 claims abstract description 3
- 229940071536 silver acetate Drugs 0.000 claims abstract description 3
- SDKPSXWGRWWLKR-UHFFFAOYSA-M sodium;9,10-dioxoanthracene-1-sulfonate Chemical compound [Na+].O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2S(=O)(=O)[O-] SDKPSXWGRWWLKR-UHFFFAOYSA-M 0.000 claims abstract description 3
- FDWREHZXQUYJFJ-UHFFFAOYSA-M gold monochloride Chemical compound [Cl-].[Au+] FDWREHZXQUYJFJ-UHFFFAOYSA-M 0.000 claims abstract 2
- 229940091250 magnesium supplement Drugs 0.000 claims description 17
- 239000002775 capsule Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 9
- 229960003035 magnesium gluconate Drugs 0.000 claims description 3
- 229940050410 gluconate Drugs 0.000 abstract description 2
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 abstract description 2
- 239000007903 gelatin capsule Substances 0.000 abstract 3
- 208000030507 AIDS Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 7
- 206010017533 Fungal infection Diseases 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 210000001165 lymph node Anatomy 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 230000008034 disappearance Effects 0.000 description 4
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 3
- 208000005577 Gastroenteritis Diseases 0.000 description 3
- 208000031888 Mycoses Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000007124 immune defense Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- KPZGRMZPZLOPBS-UHFFFAOYSA-N 1,3-dichloro-2,2-bis(chloromethyl)propane Chemical compound ClCC(CCl)(CCl)CCl KPZGRMZPZLOPBS-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- CQVDKGFMVXRRAI-UHFFFAOYSA-J Cl[Au](Cl)(Cl)Cl Chemical compound Cl[Au](Cl)(Cl)Cl CQVDKGFMVXRRAI-UHFFFAOYSA-J 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 241000726306 Irus Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/242—Gold; Compounds thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
5 5
10 10
15 15
20 20
25 25
30 30
35 35
40 40
45 45
50 50
55 55
60 60
CH 684 630 A5 CH 684 630 A5
Description Description
La présente invention se rapporte à une composition pharmaceutique à base d'oligo-éléments, pour le traitement du SIDA par voie orale. The present invention relates to a pharmaceutical composition based on trace elements, for the treatment of AIDS by the oral route.
Chacun connaît hélas ce fléau des temps modernes qu'est le SIDA (acronyme pour Syndrome d'im-muno-ûépression Acquise), état pathologique dont l'issue à plus ou moins long terme est l'effondrement des défenses immunitaires du sujet. Le SIDA est provoqué par l'intrusion dans l'organisme d'un agent viral, plus précisément d'un rétro-virus ou virus à A. R. N. (acide ribonucléique). On connaît au moins deux virus du SIDA, appelés VIH I et VIH II respectivement («VIH» pour i/irus d'immunodéficience Humaine), d'origine géographique probablement différente. Everyone is unfortunately aware of the scourge of modern times that is AIDS (acronym for Acquired Immuno-ûépression Syndrome), a pathological condition whose outcome in the more or less long term is the collapse of the subject's immune defenses. AIDS is caused by the intrusion into the body of a viral agent, more precisely of a retro-virus or virus with A. R. N. (ribonucleic acid). At least two AIDS viruses are known, called HIV I and HIV II respectively ("HIV" for i / irus of Human immunodeficiency), of probably different geographic origin.
Lorsque l'organisme est infecté par un de ces virus, transmis au cours de rapports sexuels ou par voie sanguine, la personne contaminée devient séropositive, c'est-à-dire qu'elle véhicule dans son système circulatoire des anticorps dirigés contre le virus. Dans un premier temps, la personne infectée n'est pas (encore) malade et c'est pourquoi on la qualifie souvent de «porteur sain». When the body is infected with one of these viruses, transmitted during sexual intercourse or by blood, the infected person becomes HIV positive, that is to say that it carries in its circulatory system antibodies to the virus. . At first, the infected person is not (yet) sick and that is why it is often called "healthy carrier".
Au bout d'un temps très variable, pouvant dépasser 10 ans, la personne séropositive voit ses défenses immunitaires s'effondrer brusquement et devient alors sujette à toutes sortes d'infections opportunistes. Elle déclare des maladies, qui finissent rapidement par l'emporter, faute de système immunitaire fonctionnel. On parie alors de SIDA déclaré. Ajoutons que, facteur aggravant, l'un comme l'autre rétrovi-rus VIH l et VIH II ont la faculté de se modifier et de muter très rapidement. At the end of a very variable time, which can exceed 10 years, the HIV positive person sees his immune defenses suddenly collapse and then becomes subject to all kinds of opportunistic infections. She declares illnesses, which quickly prevail over the lack of a functioning immune system. We bet then of declared AIDS. Let us add that, aggravating factor, one like the other retrovirus HIV l and HIV II have the faculty to modify and mutate very quickly.
Les efforts de recherche colossaux qui sont menées depuis ia découverte du SIDA et de l'identification de sa cause, ainsi que les fonds impressionnants qui y ont été consacrés, semblent tous basés sur le postulat qu'il faut impérativement empêcher le virus, soit de s'introduire dans les cellules responsables des défenses immunitaires (les divers lymphocytes), soit l'empêcher de se répliquer dans la cellule hôte, ce qui finit par la tuer. Les produits de la réplication se répandent alors dans l'organisme et viennent s'attaquer d'autres cellules de l'immunité. Une grosse partie de ces recherches visent donc à développer un vaccin. The colossal research efforts that have been carried out since the discovery of AIDS and the identification of its cause, as well as the impressive funds that have been devoted to it, all seem to be based on the premise that it is imperative to prevent the virus, namely to getting into the cells responsible for immune defenses (the various lymphocytes), or preventing it from replicating in the host cell, which ultimately kills it. The replication products then spread throughout the body and attack other cells of the immune system. Much of this research therefore aims to develop a vaccine.
Toute autre est l'approche ayant présidé à la mise au point de la composition selon l'invention, qui, sans nier les conceptions thérapeutiques évoquées ci-dessus, est basée sur des conceptions différentes, liées à la médecine énergétique. Quite different is the approach which presided over the development of the composition according to the invention, which, without denying the therapeutic conceptions mentioned above, is based on different conceptions linked to energy medicine.
Selon l'invention, on a en effet constaté, comme on le verra plus avant dans la partie du texte consacrée aux résultats cliniques, que l'association, au sens pharmacologique du terme, de certains oligoéléments permettait de résister victorieusement au SIDA, c'est-à-dire d'en neutraliser les effets, et même de guérir d'un SIDA déclaré, le sujet restant cependant séropositif. Ce qui est remarquable aussi, c'est que la composition pharmaceutique est active par voie orale et peut donc s'utiliser dans un contexte de clinique ambulatoire courante, sans hospitalisation. According to the invention, it has indeed been observed, as will be seen further in the part of the text devoted to clinical results, that the association, in the pharmacological sense of the term, of certain trace elements makes it possible to successfully resist AIDS, it that is to say to neutralize the effects, and even to cure a declared AIDS, the subject remaining HIV positive, however. What is also remarkable is that the pharmaceutical composition is active orally and can therefore be used in the context of a routine outpatient clinic, without hospitalization.
La composition selon l'invention comprend des sels physioiogiquement acceptables d'or, de magnésium et d'argent. Ces sels sont avantageusement dans les proportions suivantes, exprimées en parties pondérales de l'élément considéré: The composition according to the invention comprises physiologically acceptable salts of gold, magnesium and silver. These salts are advantageously in the following proportions, expressed in parts by weight of the element considered:
Or: 3 à 15 parties Gold: 3 to 15 games
Magnésium: 20 à 100 parties Magnesium: 20 to 100 parts
Argent: 2 à 10 parties avec une préférence pour la composition moyenne suivante: Silver: 2 to 10 parts with a preference for the following average composition:
Or: 5 parties Gold: 5 parts
Magnésium: 60 parties Magnesium: 60 parts
Argent: 6 parties Silver: 6 games
L'or est de préférence sous forme de tétrachlorure d'or AuCU, le magnésium sous forme de sulfate de magnésium MgSÛ4 ou de gluconate de magnésium et l'argent sous forme d'acétate d'argent (CH3COO)2Ag, ce qui correspond alors aux compositions préférées suivantes, toujours en parties pondérales: The gold is preferably in the form of gold tetrachloride AuCU, the magnesium in the form of magnesium sulfate MgS04 or magnesium gluconate and the silver in the form of silver acetate (CH3COO) 2Ag, which then corresponds to the following preferred compositions, still in parts by weight:
2 2
5 5
10 10
15 15
20 20
25 25
30 30
35 35
40 40
45 45
50 50
55 55
60 60
65 65
CH 684 630 A5 CH 684 630 A5
AuCl4: AuCl4:
MgSÛ4: MgSO4:
(CH3COO)2Ag: (CH3COO) 2Ag:
5,1 à 15,3 parties 178 à 890 parties 4,1 à 21 parties ou encore 5.1 to 15.3 parts 178 to 890 parts 4.1 to 21 parts or even
AuCU: AuCU:
Gluconate Mg: (CH3COO)2Ag: Gluconate Mg: (CH3COO) 2Ag:
5,1 à 15,3 parties 340 à 1700 parties 4,1 à 21 parties 5.1 to 15.3 parts 340 to 1,700 parts 4.1 to 21 parts
Les oligo-éléments considérés peuvent être pris par voie orale sous n'importe quelle forme convenable. Cependant, pour faciliter leur prise, la composition peut être sous une forme préparée à l'avance. Elle se présente alors avantageusement sous la forme de deux gélules au moins, qui peuvent être administrées simultanément ou séparément, une gélule contenant le sel d'or et le sel de magnésium et l'autre gélule contenant le sel d'argent. Il vaut mieux ne pas mélanger l'argent aux deux autres oligoéléments avant l'administration. The trace elements considered can be taken orally in any suitable form. However, to facilitate their setting, the composition can be in a form prepared in advance. It is then advantageously in the form of at least two capsules, which can be administered simultaneously or separately, one capsule containing the gold salt and the magnesium salt and the other capsule containing the silver salt. It is best not to mix the silver with the other two trace elements before administration.
La prise de deux gélules peut être faite sous forme d'une unité de prise par jour qui contiendra alors, de préférence, de 3 à 15 mg d'or élémentaire, de 20 à 100 mg de magnésium élémentaire, de 10 à 100 mg d'argent élémentaire. L'administration peut également être réalisée sous forme de plusieurs prises par jour, fragmentées (voir plus bas), ou encore d'une prise plus espacée dans le temps, dont les totaux journaliers donnent néanmoins les quantités susindiquées (multiples ou sous-multiples des valeurs indiquées ci-dessus, en mêmes proportions). The taking of two capsules can be made in the form of a unit of taking per day which will then preferably contain from 3 to 15 mg of elemental gold, from 20 to 100 mg of elemental magnesium, from 10 to 100 mg of elementary money. Administration can also be carried out in the form of several doses per day, fragmented (see below), or even a dose more spaced over time, the daily totals of which nevertheless give the above-mentioned quantities (multiples or submultiples of values indicated above, in the same proportions).
Une composition préférée comprend 5 mg d'or sous forme de AuCU et 60 mg de magnésium sous forme de MgSC>4 ou de gluconate de magnésium dans une gélule à base de gélatine contenant des excipients non actifs tels que du maltose; et 6 mg d'argent élémentaire sous forme (CH3COO)2Ag dans une deuxième gélule. A preferred composition comprises 5 mg of gold in the form of AuCU and 60 mg of magnesium in the form of MgSC> 4 or of magnesium gluconate in a gelatin-based capsule containing non-active excipients such as maltose; and 6 mg of elemental silver in the form (CH3COO) 2Ag in a second capsule.
La composition peut être bien sûr constituée d'autres sels physiologiquement acceptables de ces oligoéléments et, le cas échéant, inclure d'autres sels physiologiquement acceptables, pourvu qu'elle contienne au moins cette association d'oligo-éléments. The composition can of course be made up of other physiologically acceptable salts of these trace elements and, if appropriate, include other physiologically acceptable salts, provided that it contains at least this combination of trace elements.
Le tableau qui suit donne les résultats des essais cliniques qui ont été menés sur un certain nombre de patients (15) de tout âge, dont certains étaient seulement séropositifs, tandis que d'autres avaient déjà un SIDA déclaré. Les diverses colonnes reprennent respectivement la date de l'année de naissance du patient, son sexe, la date du début du traitement, son état physiologique au début du traitement et son état physiologique à la fin du traitement. The following table gives the results of clinical trials which have been carried out on a number of patients (15) of all ages, some of whom were only HIV positive, while others already had declared AIDS. The various columns show respectively the date of the year of birth of the patient, his sex, the date of the start of the treatment, his physiological state at the start of the treatment and his physiological state at the end of the treatment.
Tous ces patients ont reçu une composition selon l'invention comprenant 1,5 mg d'or élémentaire, 30 mg de magnésium élémentaire et 3 mg d'argent élémentaire, en deux ou trois prises journalières de deux gélules, la première gélule contenant l'or sous forme de tétrachlorure et le magnésium sous forme de sulfate, et la deuxième gélule contenant l'argent sous forme d'acétate. All these patients received a composition according to the invention comprising 1.5 mg of elemental gold, 30 mg of elemental magnesium and 3 mg of elemental silver, in two or three daily doses of two capsules, the first capsule containing the gold in the form of tetrachloride and magnesium in the form of sulfate, and the second capsule containing silver in the form of acetate.
3 3
5 5
10 10
15 15
20 20
25 25
30 30
35 35
40 40
45 45
50 50
55 55
CH 684 630 A5 CH 684 630 A5
Né le Born the
Sexe Sex
En traitement depuis In treatment since
Avant Before
Après After
1949 1949
M M
oct. 1990 Oct 1990
Candidas buccaux ganglions. Candidas oral lymph nodes.
Stade 3. Stage 3.
Rémission totale des affections et reprise activité professionelle à 100%. Total remission of affections and resumption of professional activity at 100%.
1957 1957
F F
juil. 1990 Jul 1990
Séropositive, premiers symptômes, fièvres. HIV positive, first symptoms, fevers.
Clinique en ordre Séropositive. Clinic in seropositive order.
1958 1958
F F
oct. 1990 Oct 1990
Début SIDA déclaré gastroentérite. Early AIDS declared gastroenteritis.
Clinique en ordre Séropositive. Clinic in seropositive order.
1942 1942
M M
avril 1990 April 1990
Kaposi, gastroentérite, fièvres, cancer intestins. Stade 4. Kaposi, gastroenteritis, fevers, intestinal cancer. Stage 4.
Régression Kaposi vitalité, montée CD4. Nette amélioration clinique avec les oligo-éléments. Kaposi vitality regression, CD4 rise. Significant clinical improvement with trace elements.
1961 1961
F F
mars 1991 March 1991
Pneumonie. Stade 1. Pneumonia. Stage 1.
Clinique en ordre Séropositif. Clinic in order HIV positive.
1947 1947
M M
mars 1991 March 1991
Kaposi, mycoses. Stade 3. Kaposi, yeast infections. Stage 3.
Force physique. Disparition des mycoses, régression Kaposi. Activité professionnelle à 100%. Physical force. Disappearance of yeast infections, Kaposi regression. 100% professional activity.
1954 1954
M M
janv. 1990 Jan 1990
Séropositif infections disséminées. HIV positive disseminated infections.
Clinique en ordre. Reprise activité professionnelle à 100%. Clinic in order. Resumption of professional activity at 100%.
1953 1953
M M
janv. 1991 Jan 1991
Kaposi, mycoses, fièvres. Stade 4. Kaposi, mycoses, fevers. Stage 4.
Mycoses et Kaposi régressés. Forme physique maintenue. Activité professionnelle 100%. Mycoses and Kaposi regressed. Maintained physical fitness. 100% professional activity.
1966 1966
M M
janv. 1991 Jan 1991
Candida, ganglions. Stade 3. Candida, lymph nodes. Stage 3.
Ganglions et candida disparus. Lymph nodes and candida disappeared.
Etat stationnaire mais se porte bien. Stationary but is doing well.
1962 1962
F F
oct. 1991 Oct 1991
Début SIDA déclaré, infections. Beginning of declared AIDS, infections.
Clinique en ordre. Clinic in order.
Activité professionnelle 100%. 100% professional activity.
1968 1968
F F
avril 1992 April 1992
Ganglions, gastroentérite, Lymph nodes, gastroenteritis,
fièvres. fevers.
Stade 4. Stage 4.
Actuellement stable. Soignée depuis 3 mois. Currently stable. Treated for 3 months.
1952 1952
M M
oct. 1990 Oct 1990
Diarrhée opportuniste, Opportunistic diarrhea,
mycoses. yeast infections.
Stade 4. Stage 4.
Disparition diarrhée, régression mycoses. Disappearance of diarrhea, mycosis regression.
Activité 100%. 100% activity.
1948 1948
M M
oct. 1990 Oct 1990
Kaposi, mycoses. Stade 2. Kaposi, yeast infections. Stage 2.
Disparition des mycoses, régression du Kaposi. Disappearance of mycoses, regression of Kaposi.
Se porte bien. Is doing well.
1936 1936
M M
août 1991 August 1991
Séropositif, ganglions. HIV positive, lymph nodes.
Ganglions disparus. Clinique en ordre. Disappearing nodes. Clinic in order.
1961 1961
F F
juin 1991 June 1991
Début SIDA déclaré, diarrhée opportuniste. Beginning of declared AIDS, opportunistic diarrhea.
Disparition de la diarrhée. Séropositif. Disappearance of diarrhea. HIV positive.
Les mécanismes d'action sont inconnus et restent à élucider, mais les résultats sont là et il est remarquable de constater que la plupart des patients, en SIDA déclaré (stades 1 à 4) ou début de SIDA déclaré, ont vu leurs maladies régresser, au point d'avoir pu pour certains déjà reprendre une existence normale. The mechanisms of action are unknown and remain to be elucidated, but the results are there and it is remarkable to note that most of the patients, with declared AIDS (stages 1 to 4) or beginning of declared AIDS, saw their illnesses regress, to the point of having been able for some already to resume a normal existence.
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH2606/92A CH684630A5 (en) | 1992-08-21 | 1992-08-21 | Pharmaceutical composition based on trace elements |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH2606/92A CH684630A5 (en) | 1992-08-21 | 1992-08-21 | Pharmaceutical composition based on trace elements |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH684630A5 true CH684630A5 (en) | 1994-11-15 |
Family
ID=4237545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH2606/92A CH684630A5 (en) | 1992-08-21 | 1992-08-21 | Pharmaceutical composition based on trace elements |
Country Status (1)
| Country | Link |
|---|---|
| CH (1) | CH684630A5 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998047497A3 (en) * | 1997-04-23 | 1999-01-21 | Fleming & Company Pharmaceutic | Methods and compositions for the prevention and treatment of immunological disorders, inflammatory diseases and infections |
| WO1999048505A1 (en) * | 1998-03-26 | 1999-09-30 | Pedro Fernandez De Haro | Pharmacological composition based on minerals |
| WO2001026669A1 (en) * | 1999-10-14 | 2001-04-19 | Sanhita Munier | A nascent gold based herbal composition |
-
1992
- 1992-08-21 CH CH2606/92A patent/CH684630A5/en not_active IP Right Cessation
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998047497A3 (en) * | 1997-04-23 | 1999-01-21 | Fleming & Company Pharmaceutic | Methods and compositions for the prevention and treatment of immunological disorders, inflammatory diseases and infections |
| WO1999048505A1 (en) * | 1998-03-26 | 1999-09-30 | Pedro Fernandez De Haro | Pharmacological composition based on minerals |
| WO2001026669A1 (en) * | 1999-10-14 | 2001-04-19 | Sanhita Munier | A nascent gold based herbal composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0548356B1 (en) | Rapidly disintegratable multiparticulate tablet | |
| US20090191288A1 (en) | Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases | |
| JPH07508724A (en) | Pharmaceutical compositions containing NSAIDs and bile acids | |
| TW200816985A (en) | Methods for buccal, lingual or sublingual dosing regimens of epinephrine for the treatment of allergic emergencies | |
| TWI269656B (en) | Therapeutical composition for hepatitis C | |
| JP3018160B2 (en) | Drug for reducing dysmenorrhea and / or premenstrual syndrome | |
| Trondstad et al. | Gastroscopic findings after treatment with enteric-coated and plain naproxen tablets in healthy subjects | |
| TW536403B (en) | An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy | |
| CH684630A5 (en) | Pharmaceutical composition based on trace elements | |
| FR2513122A1 (en) | NEW MEDICINES BASED ON ALGAE EXTRACTS AND CORRESPONDING FORMULATIONS | |
| Hamaguchi et al. | Bioavailability of mefenamic acid: influence of food and water intake | |
| US20170119707A1 (en) | Homeopathic topical gel for transdermal delivery of colchicine formulations and method of use | |
| TW200800155A (en) | Gastric retentive gabapentin dosage forms and methods for using same | |
| RU2189243C1 (en) | Compositions "ginrosin" showing general tonic and adaptogenic effect | |
| Hillson | Fungi and diabetes | |
| Freeman et al. | Relative bioavailability of atovaquone suspension when administered with an enteral nutrition supplement | |
| WO2005007070A2 (en) | Stable pharmaceutical composition | |
| EP3027064A1 (en) | Liquid or semi-liquid pharmaceutical, dietary or food composition free of bitterness containing an arginine salt | |
| JP4021505B2 (en) | Antidiabetic drugs and functional foods | |
| RU2098106C1 (en) | Method for diagnosing myasthenia | |
| US20050137265A1 (en) | Rapidly dissolving metoclopramide solid oral dosage and method thereof | |
| CN115968284A (en) | Sodium butyrate for the prevention or treatment of rhinovirus infection | |
| JP2000505433A (en) | Use of 3-amino-4-hydroxybenzoic acid for the treatment of retroviral infection | |
| WO2006015556A1 (en) | A antiviral combination and thereof manufacture | |
| EPSTEIN et al. | Cycloserine-isoniazid combination therapy in virgin cases of pulmonary tuberculosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased |